Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature

Ali H Palejwala¹, Christen M O’Neal¹, Michael R Quinton², James D Battiste¹, Jo Elle G Peterson² and Ian F Dunn¹

Abstract
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described low-grade neuroepithelial tumor with an infiltrative growth pattern and oligodendrocyte-like cells that are CD34 immunopositive. Correlating histology and results from molecular testing is critical to correctly diagnosing PLNTY, as its histologic appearance is similar to oligodendrogliomas and shares genetic abnormalities common to other low-grade epilepsy associated tumors (LEATs). In this case report, we describe a 31-year-old female with intractable epilepsy found to have a temporal mass and diagnosed with PLNTY after histopathologic and molecular testing. We describe the radiographic, histologic, and genetic features in relation to the epileptic and oncologic outcomes for this patient. Then, we compare these features and outcomes to other cases of PLNTY described in the literature.

Keywords
Polymorphous low-grade neuroepithelial tumor of the young, low-grade epilepsy associated tumors, molecular analysis, BRAF, fibroblast growth receptor2, fibroblast growth receptor3

Introduction
There are a number of glial and glioneural tumors that commonly cause drug-resistant epilepsy in pediatric and young-adult populations. These tumors are part of a group known as low-grade epilepsy associated tumors (LEATs), an umbrella of developmental tumors with varying histologic appearances, associated with early-onset seizures. Glial tumors, such as pilocytic astrocytomas or pediatric oligodendrogliomas, usually have distinct diagnostic criteria that assist in further clinical management. However, glioneuronal tumors such as ganglioglioma (GG) and dysembryoplastic neuroepithelial tumors (DNET) have less distinct diagnostic criteria and therefore present a diagnostic challenge due to high intra-observer variability in pathologic diagnosis.¹ As these entities encompass a broad neuropathologic spectrum, predicting their clinical behavior can also be challenging.

The advent of molecular diagnostic testing has assisted in treating pediatric glioneuronal and glial tumors.¹ Molecular analysis has allowed tumors to be more accurately classified based on expression profiles and methylation patterns. Attempts to further characterize these epileptogenic neoplasms have led to discoveries of distinct entities. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) was first described in 2017.² It is notable for the presence of oligodendroglioma-like cellular components, CD34 immunopositivity, and an association with cortical
dysplasia. Molecular analysis has identified frequent genetic abnormalities involving the BRAF proto-oncogene or fibroblast growth receptor (FGFR), along with a distinct methylation pattern. It lacks isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletion.

In our case report, we describe a 31-year-old female with intractable epilepsy found to have a temporal mass. We aim to describe our epileptic and oncologic outcomes, comparing it with other cases described in the literature.

**Case report**

Our patient was a 31-year-old right-handed female who had been experiencing intermittent seizures over the past two years. They were described as intermittent episodes of tongue tingling, decreased hearing, and inability to concentrate, occurring approximately once per week. The patient felt these episodes were triggered by stress. Her condition progressed until she experienced a generalized tonic-clonic seizure in October 2020. A CT brain without contrast demonstrated an intra-axial mass within the right temporal lobe (Figure 1(a)–(d)). The mass was cystic with hyperdensities thought to represent coarse calcifications in the periphery.

An MRI brain with and without contrast demonstrated a predominantly cystic, well-circumscribed, intra-axial lesion within the right temporal lobe measuring 1.8 × 2.2 × 1.8 cm. The mass did not enhance on post-contrast T1 weighted imaging (T1WI) and demonstrated hyperintensity on T2WI in the predominant cystic portion of the tumor. There was adjacent T2WI hyperintensity, which was felt to represent adjacent cerebral edema. Diffusion-tensor imaging demonstrated no involvement of major white matter tracts.

Following informed consent, the patient underwent a right temporal craniotomy for resection of the mass. Under the microscope, the dura was opened and a small cortical resection was performed. A small, fluid-filled mass with calcification and a thin tumor capsule was encountered and resected. No intraoperative complications were encountered and an MRI on postoperative day 1 demonstrated complete resection of the mixed solid and cystic lesion (Figure 1(e)).

Hematoxylin and eosin staining demonstrated a hypercellular lesion composed of small, monomorphic cells resembling oligodendrocytes and scattered micro-calciﬁcations (Figure 2). The original panel of immunohistochemical staining performed at the time of diagnosis suggested the presence of an IDH mutation. Therefore, the diagnosis of oligodendroglioma was originally made. However, sequencing of the tumor demonstrated the wild-type IDH1 and IDH2 genes, indicating the IDH immunohistochemical staining was nonspeciﬁc (false positive). In addition, the 1p19q co-deletion, the molecular signature of an oligodendroglioma, was not identiﬁed on chromosomal microarray. Instead, the tumor harbored a BRAF V600E mutation. Immunohistochemical staining with CD34 was diffusely positive, confirming a diagnosis of PLNTY.

The patient was readmitted two months later due to an episode of ringing in her ears and numbness of her tongue. An electroencephalogram demonstrated right temporal intermittent rhythmic delta activity, consistent with cortical irritability and the patient was diagnosed with a breakthrough seizure. After a dosage increase in her anti-epileptic regimen,
the patient had no other seizures. An MRI brain with and without contrast at 3 months following surgery demonstrated no concern for recurrent disease (Figure 1(f)–(g)). However, there was evidence of prior blood products as suggested by a FLAIR abnormality anterior to the cavity, which was similar to the preoperative film (Figure 1(d) and (h)).

Discussion

PLNTY is a recently described low-grade neuroepithelial tumor which has an infiltrative growth pattern, oligodendrocyte-like cells that stain with CD34 immunopositivity, and either BRAF mutation or FGFR2/FGFR3 translocation. We compare the imaging characteristics with oncologic and epileptogenic outcomes in other reported cases of PLNTY to further elucidate its morphology and behavior.

Concordance with histology

PLNTY is a low-grade tumor comprised of infiltrating “oligodendrocyte-like” cells with frequent calcifications. It is often associated with cortical dysplasia. The diagnostic challenge most often involves distinguishing this tumor from an oligodendroglia, given the significant morphologic and clinical overlap. CD34 immunohistochemical staining can be helpful in making this distinction, with oligodendrogliomas staining negatively while PLNTY stain positively. Markers of glial differentiation, like GFAP and Olig2, may be positive in both. Importantly, PLNTY lacks neuronal differentiation and should not stain with neuronal markers such as NeuN. This helps to distinguish PLNTY from other tumors in the LEAT differential diagnosis. Often, the final diagnosis is made by interpreting the histology in light of the molecular profile. While oligodendrogliomas harbor IDH mutations and 1p/19q codeletions, PLNTY do not. Instead, they often demonstrate alterations in BRAF or FGFR2/FGFR3. Consistent with its low-grade classification, a Ki-67 labeling index will be low, typically less than 5%.

CD34 is a transmembrane phosphoglycoprotein that is found in progenitor cells and is expressed during early neurulation. It is not expressed in mature brain cells. Detecting the presence of CD34 is important, as CD34 positive lesions have been shown to be associated with a greater degree of drug-resistant epilepsy.

BRAF V600E mutation

BRAF V600E is a missense mutation in which there is a replacement of valine with glutamic acid at codon 600. It is believed that this amino acid replacement at the N-terminal site creates a gain-of-function postulated to create a conformation that is similar to the phosphorylated state of the protein. This allows it to activate the MAP kinase pathway in the absence of external signals. This mutation has different effects on cells. In cells that are destined for neuronal lineage, it has been shown to lead to increased neuron size.
Table 1. Reported cases of PLNTY in the literature.

| Study                  | Number of patients | Age and sex | Clinical presentation | Duration of symptoms | Location             | Imaging characteristics                      | Treatment                                                                 | Length of follow-up | Outcome                          | Reported mutation                        |
|------------------------|--------------------|-------------|-----------------------|----------------------|----------------------|-----------------------------------------------|---------------------------------------------------------------------------|---------------------|-----------------------------------|------------------------------------------|
| Bale et al., 2021      | 1                  | 15 F        | Seizure               | NR                   | L Medial Temporal Lobe | Calciified, cystic, circumscribed, enhancing | GTR with recurrence 17 months post-resection, treated with NTR, focal proton radiotherapy, and TMZ | 34 months           | NR                               | FGFR3-TACC3 (original tumor and recurrence) |
| Bitar et al., 2018     | 1                  | 31 M        | Focal epilepsy refractory to partial temporal lobectomy | NR                   | R Posterior Temporal Lobe | NR                              | GTR without recurrence                                                     | 12 months           | Seizure Freedom                  | BRAF V600E                              |
| Chen et al., 2020      | 3                  | 14 F        | Focal epilepsy        | 1 year               | L Temporal Lobe       | Calciified                                     | GTR without recurrence                                                     | 3 months            | Seizure Freedom                  | FGFR3-TACC3                              |
|                        |                    | 15 M        | Focal epilepsy        | 6 months             | R Temporal Lobe       | Calciified, circumscribed, enhancing           | GTR without recurrence                                                     | 3 months            | Seizure Freedom                  | BRAF V600E                              |
|                        |                    | 16 M        | Focal epilepsy        | 2 years              | R Frontal Lobe        | Calciified, cystic, enhancing                  | GTR without recurrence                                                     | 36 months           | Seizure Freedom                  | Not tested                              |
| Gupta et al., 2019     | 1                  | 30 M        | Focal epilepsy        | 8 years              | R Anterior Temporal Lobe | Circumscribed                                   | GTR without recurrence                                                     | 10 months           | Seizure Freedom                  | BRAF V600E                              |
| Huse et al., 2016      | 10                 | 16 M        | Epilepsy              | More than 2 years    | R Medial Temporal Lobe | NR                              | GTR without recurrence                                                     | 53 months           | Seizure Freedom                  | BRAF V600E                              |
|                        |                    | 18 F        | Epilepsy              | 1 year               | R Medial Temporal Lobe | Enhancing                                      | STR with stable disease on imaging                                         | 18 months           | Seizure Freedom                  | BRAF V600E                              |
|                        |                    | 23 F        | Epilepsy              | Unknown              | R Temporal Lobe       | NR                              | GTR without recurrence                                                     | NR                  | NR                               | BRAF V600E                              |
|                        |                    | 17 F        | Epilepsy              | Unknown              | R Temporal Lobe       | NR                              | GTR without recurrence                                                     | NR                  | NR                               | FGFR3-TACC3                              |
|                        |                    | 4 M         | Epilepsy              | Unknown              | L Temporal Lobe       | NR                              | GTR without recurrence                                                     | NR                  | NR                               | FGFR2-CTNNA3                             |
|                        |                    | 9 M         | Epilepsy              | 6 years              | R Frontal Lobe        | Calciified, cystic, enhancing                  | GTR with new FLAIR signal abnormalities at 36 months post-resection        | 36 months           | Seizure recurrence               | FGFR2-KIAA1598                           |
|                        |                    | 10 M        | Headaches and dizziness | 6 days              | R Occipital Lobe      | NR                              | GTR without recurrence                                                     | 62 months           | N/A                              | FGFR2-KIAA1598                           |
|                        |                    | 23 F        | Epilepsy              | NR                   | R Medial Temporal Lobe | NR                              | GTR without recurrence                                                     | 12 months           | NR                               | No BRAF mutation, FGFR not tested       |
|                        |                    | 32 F        | Epilepsy              | 26 years             | R Temporal Lobe       | NR                              | GTR without recurrence                                                     | 55 months           | Seizure Freedom                  | Not tested                              |
|                        |                    | 24 F        | Visual disturbances   | 2 years              | R Occipital Lobe      | NR                              | GTR without recurrence                                                     | 12 months           | N/A                              | Not tested                              |

(continued)
| Study | Number of patients | Age and sex | Clinical presentation | Duration of symptoms | Location | Imaging characteristics | Treatment | Length of follow-up | Outcome | Reported mutation |
|-------|-------------------|-------------|-----------------------|----------------------|----------|------------------------|-----------|---------------------|---------|-------------------|
| Johnson et al., 2019 | 9 | 12 F | NR | NR | L Temporal Lobe | Calci, cystic, circumscribed | NR | NR | NR | FGFR2-KIAA1598 |
| | 12 F | NR | NR | L Parietal Lobe | Calci, cystic, circumscribed | NR | NR | NR | FGFR2 rearrangement |
| | 26 F | NR | NR | L Temporal Lobe | Calci, cystic, circumscribed, enhancing | NR | NR | NR | BRAF V600E |
| | 16 F | NR | NR | R Temporal Lobe | Calci, cystic, circumscribed | NR | NR | NR | BRAF Fusion |
| | 25 M | NR | NR | R Temporal Lobe | Cystic | NR | NR | NR | BRAF V600E |
| | 15 F | NR | NR | L Temporal Lobe | Calci, cystic, circumscribed | NR | NR | NR | None |
| | 5 F | NR | NR | R Parietal Lobe | Calci, cystic, circumscribed | NR | NR | NR | FGFR2-KIAA1598 |
| | 34 M | NR | NR | R Temporal Lobe | Calci, cystic, circumscribed, enhancing | NR | NR | NR | BRAF V600E |
| | 17 F | NR | NR | Third Ventricle | Calci, cystic, circumscribed, enhancing | NR | NR | NR | BRAF V600E |
| Riva et al., 2018 | 1 | 57 M | Headache | Less than 1 month | R Frontal Lobe | Cystic | Unspecified resection without recurrence | 12 months | N/A | FGFR3-TACC3 |
| Sumdani et al., 2019 | 1 | 19 M | Epilepsy and headache | 4 months | R Parietal Lobe | Calci, cystic, circumscribed | Unspecified resection without recurrence | NR | Seizure recurrence | BRAF V600E |
| Surrey et al., 2019 | 6 | 7 M | Epilepsy | NR | Temporal Lobe | Cystic | GTR | 8 months | NR (disease not progressive) | FGFR2-INA |
| | 10 F | Epilepsy | NR | Parietal Lobe | - | GTR with recurrence 60 months post-resection | 82 months | NR | FGFR2-INA |
| | 14 M | Epilepsy | NR | Parietal and Temporal Lobes | Cystic | STR without recurrence | 10 months | NR | FGFR2-CTNNA3 |
| | 16 M | Epilepsy | NR | Temporal Lobe | - | GTR without recurrence | 10 months | NR | BRAF V600E |
| | 8 M | Epilepsy | NR | Temporal Lobe | Cystic | GTR without recurrence | 5 months | NR | BRAF V600E |
| | 14 F | Epilepsy, vomiting | NR | Temporal and Occipital Lobes | Cystic | STR without recurrence | 60 months | NR | BRAF V600E |
| Tateishi et al., 2020 | 1 | 14 M | Epilepsy | 1 year | L Temporal Lobe | Calci, cystic, circumscribed | GTR without recurrence | 16 months | Seizure Freedom | BRAF V600E |

Abbreviations: F = Female; GTR = Gross Total Resection; L = Left; M = Male; N/A = Not applicable; NR = Not reported; NTR = Near Total Resection; PLNTY = Polymorphous Low-Grade Neuroepithelial Tumor of the Young; R = Right; STR = Sub-total Resection; TMZ = Temozolomide.
and epileptogenic potential. In cells of glial origin, it leads to proliferative capabilities. BRAF V600E mutations are not only associated with PLNTY but are also common in gangliogliomas, another member of the LEAT family. This mutation has also been described in other tumors of the central nervous system, including papillary craniopharyngioma and pleomorphic xanthoastrocytoma (PXA), and with much less frequency in pilocytic astrocytoma, anaplastic astrocytoma, epithelioid glioblastoma, gliosarcoma, rhabdoid meningioma, and atypical teratoid/rhabdoid tumor (AT/RT).

**FGFR alterations**

The FGFR family is a group of transmembrane tyrosine kinase receptors (FGFR1-4) which homodimerize when ligand-bound and trigger downstream pathways including the MAPK and PI3K/Akt/mTOR pathways. Alterations in FGFR2 and FGFR3 have been described in PLNTY, with a number of different fusion partners. In a series by Surrey et al., fusions involving FGFR2 were identified, including a case with the rare FGFR2-CTNNA3 fusion. In the original description of PLNTY, Huse et al. identified multiple fusions involving FGFR2 and FGFR3, including FGFR3-TACC3, FGFR2-KIAA198, and FGFR2-CTNNA3. These fusions were mutually exclusive with BRAF mutations. The result of these fusions is homodimerization and autophosphorylation of downstream effectors leading to enhanced activation of the MAP kinase pathway. FGFR3-TACC3 fusion has also been described in a subset of glioblastomas and other gliomas. This particular fusion product was present in the only documented case of PLNTY with malignant transformation. The presence of FGFR alterations does not help to distinguish PLNTY from other tumors in the LEAT differential diagnosis, as they have also been reported in many of these tumors.

Of the 29 cases in the literature with documented molecular analysis, 16 harbored BRAF V600E mutations while 13 had FGFR fusion (Table 1). Upon reviewing these cases we identified in the literature, there were no overt differences in oncologic or epilepsy-associated outcomes based on molecular profiles. Further research is required to characterize the effect specific molecular profiles have on patient outcomes in PLNTY.

**Imaging Concordance**

The prototypical description of PLNTY is a well-circumscribed lesion with a calcified and cystic component. These lesions have been reported to be primarily in the temporal lobe. In our review of the literature, we found that a majority of these tumors were located on the right side. As was seen in our case, PLNTY are primarily cystic with frequent calcification.

**Association with Focal Cortical Dysplasia**

The association with epilepsy has been linked to the expression of CD34 and BRAF V600E mutation. These low-grade epilepsy associated tumors are associated with focal cortical dysplasia (FCD) and are classified as FCD type IIb according to the ILAE classification system. FCD in addition to other features of PLNTY may contribute to a prolonged disease course in these patients, as CD34 immunopositivity has been associated with chronic epilepsy.

**Prognosis and Clinical Course**

Given the overlap between the clinical, radiologic, and histopathologic presentation of this tumors with others, specifically oligodendroglioma, the potential for misdiagnosis is significant. PLNTY is associated with an indolent course and seizure control can typically be attained with gross-total resection. Oligodendroglioma is associated with a lower rate of epilepsy and a worse clinical prognosis. Accurate diagnosis is critical in predicting clinical behavior and developing a treatment plan.

**Conclusion**

PLNTY is a low-grade epilepsy associated tumor associated with CD34 immunopositivity, cortical dysplasia, and either BRAF V600E mutation or FGFR2/FGFR3 fusions. As the histopathologic classification is challenging, molecular characterization can play a critical role in the diagnosis.

**Contributorship**

All authors made significant contributions and have approved the final manuscript.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethical Approval**

(Include full name of committee approving the research and if available mention reference number of that approval): This study was conducted in accordance with the Helsinki Declaration as revised in 2013. IRB approval was not required for the presentation of a single patient’s case.

**Informed Consent**

Informed verbal consent was obtained from the patient reported in this manuscript.
References

1. Delev D, Daka K, Heynekse S, et al. Long-term epilepsy-associated tumors: transcriptional signatures reflect clinical course. Sci Rep 2020; 10: 96. DOI: 10.1038/s41598-019-56146-y.

2. Huse JT, Snuderl M, Jones DT, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017; 133: 417–429. DOI: 10.1007/s00401-016-1639-9.

3. Gupta VR, Giller C, Kolhe R, et al. Polymorphous low-grade neuroepithelial tumor of the young: a case report with genomic findings. World Neurosurg 2019; 132: 347–355. DOI: 10.1016/j.wneu.2019.08.221.

4. Vornetti G, Marucci G, Zenesini C, et al. Relationship among clinical, pathological and bio-molecular features in low-grade epilepsy-associated neuroepithelial tumors. J Clin Neurosci 2017; 44: 158–163. DOI: 10.1016/j.jocn.2017.06.022.

5. Srinivasa K, Giannini C, Jenkins RB, et al. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 2019; 61: 1327–1332. DOI: 10.1007/s00234-019-02269-y.

6. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011; 52: 158–174. DOI: 10.1111/j.1528-1167.2010.02777.x.

7. Johnson DR, Giannini C, Jenkins RB, et al. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 2019; 61: 1327–1332. DOI: 10.1007/s00234-019-02269-y.

8. Bale TA, Sait SF, Benhamida J, et al. Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathol 2021; 141: 123–125. DOI: 10.1007/s00401-020-02245-4.

9. Johnson DR, Giannini C, Jenkins RB, et al. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 2019; 61: 1327–1332. DOI: 10.1007/s00234-019-02269-y.

10. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011; 52: 158–174. DOI: 10.1111/j.1528-1167.2010.02777.x.

11. Surrey LF, Jain P, Zhang B, et al. Genomic analysis of dysembryoplastic neuroepithelial tumor spectrum reveals a diversity of molecular alterations dysregulating the MAPK and P13K/mTOR Pathways. J Neuropathol Exp Neurol 2019; 78: 1100–1111. DOI: 10.1093/jnen/nnz101.

12. Riva G, Cima L, Villanova M, et al. Low-grade neuroepithelial tumor: unusual presentation in an adult without history of seizures. Neuropathology 2018; 38: 557–560. DOI: 10.1111/neup.12504.

13. Kerkhof M, Benit C, Duran-Pena A, et al. Seizures in oligodendrogial tumors. CNS Oncol 2015; 4: 347–356. DOI: 10.2217/cns.15.29.

14. Chen Y, Tian T, Guo X, et al. Polymorphous low-grade neuroepithelial tumor of the young: case report and review focus on the radiological features and genetic alterations. BMC Neurol 2020; 20: 123. DOI: 10.1186/s12883-020-01679-3.

15. Tateishi K, Ikegaya N, Udaka N, et al. BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young. Acta Neuropathol Commun 2020; 8: 139. DOI: 10.1186/s40478-020-01023-3.